MYE0 Stock Overview
A life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
MaxCyte, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£2.44 |
| 52 Week High | UK£4.96 |
| 52 Week Low | UK£2.00 |
| Beta | 1.13 |
| 1 Month Change | 7.96% |
| 3 Month Change | -39.90% |
| 1 Year Change | -29.89% |
| 3 Year Change | -50.81% |
| 5 Year Change | n/a |
| Change since IPO | -66.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| MYE0 | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | 4.3% | 4.3% | 3.4% |
| 1Y | -29.9% | -2.9% | 15.0% |
Return vs Industry: MYE0 underperformed the German Life Sciences industry which returned -3.1% over the past year.
Return vs Market: MYE0 underperformed the German Market which returned 14.4% over the past year.
Price Volatility
| MYE0 volatility | |
|---|---|
| MYE0 Average Weekly Movement | 10.5% |
| Life Sciences Industry Average Movement | 7.3% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 3.1% |
Stable Share Price: MYE0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: MYE0's weekly volatility (10%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 114 | Maher Masoud | www.maxcyte.com |
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols.
MaxCyte, Inc. Fundamentals Summary
| MYE0 fundamental statistics | |
|---|---|
| Market cap | €257.21m |
| Earnings (TTM) | -€36.27m |
| Revenue (TTM) | €34.13m |
7.5x
P/S Ratio-7.1x
P/E RatioIs MYE0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MYE0 income statement (TTM) | |
|---|---|
| Revenue | US$38.63m |
| Cost of Revenue | US$7.10m |
| Gross Profit | US$31.53m |
| Other Expenses | US$72.58m |
| Earnings | -US$41.05m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
May 07, 2025
| Earnings per share (EPS) | -0.39 |
| Gross Margin | 81.62% |
| Net Profit Margin | -106.29% |
| Debt/Equity Ratio | 0% |
How did MYE0 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/05 15:28 |
| End of Day Share Price | 2025/05/05 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
MaxCyte, Inc. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mark Massaro | BTIG |
| Matthew Hewitt | Craig-Hallum Capital Group LLC |
| Paul Cuddon | Numis Securities Ltd. |